Search

A newly published study demonstrates that imaging with Positron Emission Tomography (PET) using a radiolabeled antibody accurately identifies whether a patient has clear cell renal carcinoma - the most common and aggressive type of renal tumor - and arms the urologist with crucial information that will help determine whether surgery is needed.

… Tuesday, March 6, 2007 The ability to identify an individual’s specific tumor type prior to surgery could have important implications for the management of patients diagnosed with kidney cancer . A newly published study demonstrates that imaging with Positron Emission Tomography (PET) using a radiolabeled

Learn how noninvasive prenatal tests designed to screen for genetic abnormalities in the fetus may detect the presence of cancer in pregnant women.

… Monday, October 6, 2025 Once reserved for high-risk pregnancies, noninvasive prenatal tests (NIPTs) that screen for genetic abnormalities have been the standard of care since 2020. Most pregnant women — some 2 million a year — elect to have the test. Now a new study has found that in some cases, NIPT

In an unusual collaboration, scientists from MSK and the American Museum of Natural History looked at how the BRCA2 gene differs between humans and chimps. Mutations in this gene are linked to an increased risk of certain cancers, including breast cancer.

… Wednesday, August 31, 2022 Chimpanzees are our closest living relatives, descending from the same species as humans more than 6 million years ago. The fact that we share 98.8% of our genes with chimps explains fascinating similarities in our behaviors and our bodies. But the remaining 1.2% of genes explains

In this new expanded role, Avice Meehan will streamline communications across the Center and lead both Memorial Sloan Kettering’s Public Affairs and Marketing endeavors.

… Tuesday, March 12, 2013 Memorial Sloan Kettering Cancer Center has announced the appointment of Avice Meehan to Vice President of Communications and Chief Communications Officer. In this new expanded role, Meehan will streamline communications across the Center and lead both Memorial Sloan Kettering’

A new Sloan Kettering Institute program will enhance the use of chemical principles to investigate biological processes.

… Tuesday, August 18, 2015 Summary MSK has established the Chemical Biology Program to leverage the growing role of chemistry in biomedical research. Highlights This is the first new SKI program in more than a decade. Members will use chemical tools to study biology. Chemist Derek Tan will chair the new

From atherosclerosis and diabetes to liver fibrosis and osteoarthritis, senescent cells are at the root of many debilitating diseases. Scientists increasingly have them in the crosshairs.

… Wednesday, June 17, 2020 Summary Scientists at Memorial Sloan Kettering have genetically engineered immune cells to find and kill cells that contribute to diseases caused by senescence, a tissue-damaging inflammatory process. Studies in mice show that these engineered cells can kill their targets without

Dr. Sadelain received the award for his research on chimeric antigen receptors (CARs) and their use in providing tailored cancer treatment to patients.

… Tuesday, December 17, 2019   Michel Sadelain , Director of the Center for Cell Engineering and the incumbent of the Stephen and Barbara Friedman Chair at Memorial Sloan Kettering, received the 2019 International Prize from Inserm (Institut national de la santé et de la recherche médicale), or the French

A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.

… Wednesday, April 4, 2012 A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident. There are currently no FDA-approved treatments or

Michael P. Harrington has been named Executive Vice President and Chief Financial Officer (CFO) at Memorial Sloan Kettering Cancer Center (MSK). Mr. Harrington currently serves as the Associate Chief Financial Officer at the Cleveland Clinic. His appointment concludes a national search to identify a successor for MSK’s current CFO, Michael Gutnick, who will retire after 42 years of exemplary service to MSK.

… Wednesday, April 10, 2019 Michael P. Harrington has been named Executive Vice President and Chief Financial Officer (CFO) at Memorial Sloan Kettering Cancer Center (MSK). Mr. Harrington currently serves as the Associate Chief Financial Officer at the Cleveland Clinic. His appointment concludes a national

Learn about MSK’s leadership in developing vaccines that teach the immune system to fight cancer.

… Friday, June 6, 2025 Remarkably, the idea that a patient’s own immune system could fight cancer is more than a century old. The first notion of a cancer vaccine came back in 1893. Memorial Sloan Kettering Cancer Center (MSK) bone surgeon and cancer researcher William Coley, MD, noticed that patients